EUCTR2007-003793-26-ES进行中（未招募）不适用
Estudio de fase 3b, aleatorizado y abierto de bevacizumab (Avastin®) + temsirolimus (Torisel®) frente a bevacizumab (Avastin®) + interferón alfa (Roferon®) como tratamiento de primera línea en pacientes con carcinoma de células renales avanzadoPhase 3b, Randomized, Open-Label Study of Bevacizumab (Avastin®) + Temsirolimus(Torisel®) vs. Bevacizumab (Avastin®) + Interferon-Alfa (Roferon®) as First-LineTreatment in Subjects With Advanced Renal Cell Carcinoma
Wyeth Research Division of Wyeth Pharmaceuticals Inc.0 个研究点目标入组 800 人开始时间: 2008年3月27日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 800
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Male or female subjects greater than or equal to 18 years.
- •2. Subject with histologically and/or cytologically confirmed, advanced (stage IV or recurrent) RCC, for whom a majority component of conventional clear-cell type is mandatory. (Subjects with predominantly papillary or sarcomatoid features, and subjects with chromophobe, oncocytoma, collecting duct tumors, Bellini tumors or transitional cell carcinoma are not allowed.)
- •3. At least 1 measurable lesion (per RECIST).
- •4. Karnofsky Performance Status greater than or equal to 70.
- •5. Screening laboratory values within the following parameters:
- •ANC: > or equal to 1.5 x 109/L (1500/mm3)
- •Platelet count: > or equal to 100 x 109/L (100,000/mm3)
- •Hemoglobin: > or equal to 8.0 g/dL (80g/L) without transfusion within 2 weeks of first dose of test article
- •Serum creatinine < or equal to 1.5 x upper limit of normal (ULN)
- •Total bilirubin < or equal to 1.5 x upper limit of normal (ULN)
- •AST and ALT < or equal to 2.5 x upper limit of normal (ULN) [< or equal to 5 x upper limit of normal (ULN) with liver metastases]
- •Fasting serum cholesterol < or equal to350 mg/dL (9.0 mmol/L)
- •Fasting serum triglycerides < or equal to 400 mg/dL (4.56 mmol/L)
- •HgbA1c < 10% (optimal therapy permitted)
- •INR and PTT < or equal to 1.5 (Anticoagulation is allowed if target INR <3 and INR is therapeutic on a stable dose of a coumarin type anticoagulation, or if the subject is on a stable dose of LMW heparin for >2 weeks at time of randomization.)
- •6. QTc interval < or equal to 450 msec for males and < or equal to 470 msec for females.
- •7. Life expectancy of at least 12 weeks.
- •8. Signed and dated institutional review board (IRB) or independent ethics committee (IEC) approved informed consent form before any protocol-specific screening procedures
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Prior systemic treatment for RCC in the neoadjuvant, adjuvant or metastatic setting. Prior treatment with bevacizumab, temsirolimus, sirolimus, IFN, sunitinib or sorafenib, for any indication.
- •2. Evidence of current or prior central nervous system (CNS) metastases or any imaging abnormality indicative of CNS metastases or spinal cord compression.
- •3. Major surgery (incl. open biopsy) or radiation therapy within 28 days prior to randomization. (Palliative radiotherapy to painful bone lesions is allowed within 14 days prior to randomization). Subject must have recovered from prior surgery and radiation.
- •4. Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days prior to randomization.
- •5. Significant cardiovascular disease defined as congestive heart failure (NYHA Class II, II, or IV), angina pectoris requiring nitrate therapy, or myocardial infarction within the last 6 months;
- •6. Inadequately controlled hypertension (defined as a blood pressure of > or equal to 150 mmHg systolic and/or > or equal to 100 mmHg diastolic on medication), or any prior history of hypertensive crisis or hypertensive encephalopathy.
- •7. History of stroke or transient ischemic attack within 6 months prior to randomization
- •8. Significant vascular disease (e.g., aortic aneurysm, aortic dissection), or symptomatic peripheral vascular disease
- •9. Known congenital long QT syndrome, history of torsades de pointes or ventricular tachycardia.
- •10. Known pulmonary hypertension or pneumonitis.
- •11. More than 1 episode of DVT/PE within the last 6 months.
- •12. Evidence or history of bleeding diathesis or coagulopathy.
- •13. Chronic daily aspirin >325 mg/day or clopidogrel (>75 mg/day)
- •14. History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to randomization
- •15. Any of the following serious, non-healing conditions: wound, ulcer, or bone fracture
- •16. Proteinuria at screening as demonstrated by either:
- •- Urine dipstick > or equal to 2+ (subjects discovered to have a > or equal to 2+ proteinuria on dipstick urinalysis at baseline should undergo 24-hour urine collection and must demonstrate < or equal to 1g of protein in 24 hours to be eligible.
- •- 24-hour urine collection demonstrates > or equal to 1g of protein in 24 hours.
- •17. Immunocompromised subjects, including known seropositivity for human immunodeficiency virus (HIV), or current or chronic hepatitis B and/or hepatitis C infection (as detected by positive testing for hepatitis B surface antigen [HbsAg] or antibody to hepatitis C virus [anti HCV] with confirmatory testing. Note: Testing is not mandatory to be eligible for the study.)
- •18. Chronic treatment with corticosteroids (prednisone > or equal to 12.5 mg/day or dexamethasone > or equal to 2 mg/day) excluding inhaled steroids.
- •19. Pregnant or nursing women, women of childbearing potential not using a medically acceptable contraceptive method, or men not using a medically acceptable contraceptive method with partners of childbearing potential. A woman of childbearing potential is defined as a woman who is biologically capable of becoming pregnant. Subjects (men and women) must agree to use medically accepted contraceptive methods for 12 weeks after the last dose of study drug.
- •20. Known hypersensitivity to any component of the test articles or excipients, or documented medical condition that would prohibit adequate pre-medication with antihistamine.
- •21. Current ac
研究者
相似试验
进行中（未招募）
1 期
Estudio en fase 3B, aleatorizado y abierto para evaluar la seguridad y la eficacia de una pauta con un solo comprimido de emtricitabina/rilpivirina/tenofovir disoproxil fumarato en comparación con una pauta con un solo comprimido de efavirenz/emtricitabina/tenofovir disoproxil fumarato en adultos infectados por el VIH-1 que no han recibido tratamiento antirretroviral.A Phase 3B, Randomized, Open-label Study to Evaluate the Safety and Efficacy of a Single Tablet Regimen of Emtricitabine/Rilpivirine/Tenofovir Disoproxil FumarateCompared with a Single Tablet Regimen of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naïve Adults.Infección por el VIH-1Human Immunodeficiency Virus (Type 1) InfectionMedDRA version: 12.1Level: LLTClassification code 10020192Term: HIV-1EUCTR2010-024007-27-ESGilead Sciences, Inc.799
进行中（未招募）
不适用
Estudio fase III b, aleatorizado, abierto, para evaluar la viabilidad de primovacunación con una dosis única de la vacuna conjugada contra el meningococo del grupo C (NeisVac-C) en lactantes.A phase IIIB, randomized, open label, feasibility study of a single priming dose of meningococcal group c conjugate vaccine (NeisVac-C) in infants.Inmunización activa para la prevención de la enfermedad meningocócica invasiva causada por Neisseria meningitidis del serogrupo CMedDRA version: 13Level: LLTClassification code 10028911Term: Infección por Neisseria meningitidis NEOMEUCTR2010-019383-36-ESBaxter Innovations GmbH948
进行中（未招募）
不适用
Estudio de fase 3, abierto y aleatorizado, de inotuzumab ozogamicina (CMC-544) administrado en combinación con rituximab, comparado con un tratamiento definido a elección del investigador, a sujetos con linfoma no Hodgkin de células B folicular, CD22 positivo, en recidiva o refractarioAn Open-Label, Randomized, Phase 3 Study of Inotuzumab Ozogamicin (CMC-544) Administered in Combination With Rituximab Compared to a Defined Investigator’s Choice Therapy in Subjects With Relapsed or Refractory, CD22- Positive, Follicular B-Cell Non Hodgkin’s LymphomaEUCTR2007-000219-27-ESWyeth Research Division of Wyeth Pharmaceuticals Inc978
进行中（未招募）
不适用
Estudio de fase 3, abierto y aleatorizado, de bosutinib comparado con imatinib en sujetos con leucemia mieloide crónica cromosoma Filadelfia positiva en fase crónica, de diagnóstico recienteA Phase 3 Randomized, Open-Label Study of Bosutinib Versus Imatinib in Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive Chronic Myelogenous LeukemiaEUCTR2007-003780-50-ESWyeth Research Division of Wyeth Pharmaceuticals Inc.412
进行中（未招募）
1 期
?Estudio en Fase 3, aleatorizado y abierto de la eficacia y seguridad de crizotinib frente a pemetrexed /cisplatino o pemetrexed /carboplatino en pacientes no tratados previamente con carcinoma de pulmón no escamoso que entrañe una situación de translocación o inversión con implicación del locus del gen quinasa del linfoma anaplásico (ALK)?PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF THE EFFICACY AND SAFETY OF CRIZOTINIB VERSUS PEMETREXED/CISPLATIN OR PEMETREXED/CARBOPLATIN IN PREVIOUSLY UNTREATED PATIENTS WITH NON-SQUAMOUS CARCINOMA OF THE LUNG HARBORING A TRANSLOCATION OR INVERSION EVENT INVOLVING THE ANAPLASTIC LYMPHOMA KINASE (ALK) GENE LOCUSCáncer de pulmón no microcítico (CPNM)Non-small cell lung cancer (NSCLC)MedDRA version: 12.1Level: LLTClassification code 10029519Term: Non-small cell lung cancer stage IIIEUCTR2010-021336-33-ESPfizer, S.A.344